Kura Oncology, Inc.
KURA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001422143
In the last 90 days, Kura Oncology, Inc. insiders filed 2 open-market purchases and 3 sales; 221 institutions reported holding it in 13F filings for Q2 2026, worth $956.1M in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $2.35M in total
- 2
- Insider sellsLast 90 days, $673.9K in total
- 3
- 13F holdersQ2 2026, +2 vs. previous quarter
- 221
- 13F valueReported value at the end of Q2 2026
- $956.1M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding KURA, Q2 2026
No superinvestor reported holding KURA at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Kura Oncology, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 25, 2026 (view filing)4:05 PM ET | Sep 24 | 1 day | Burrows FrancisChief Scientific Officer | SSale | −20.7K | $10.83 | −$224.5K | −32.9%42.3K after | |
| Aug 24, 2026 (view filing)5:30 PM ET | Aug 24 | Same day | Wilson Troy EdwardPresident and CEO | PPurchase | +100.0K | $12.39 | +$1.24M | +26.4%479.2K after | |
| Aug 24, 2026 (view filing)5:30 PM ET | Aug 21 | 3 days | Powl Brian T.Chief Commercial Officer | SSale | −4.34K | $11.89 | −$51.7K | −2.5%169.3K after | 10b5-1 |
| Aug 21, 2026 (view filing)4:30 PM ET | Aug 19 | 2 days | Bair Teresa BrophyChief Legal Officer | SSale | −31.5K | $12.63 | −$397.7K | −13.9%195.4K after | 10b5-1 |
| Aug 17, 2026 (view filing)4:45 PM ET | Aug 17 | Same day | Wilson Troy EdwardPresident and CEO | PPurchase | +100.0K | $11.12 | +$1.11M | +35.8%379.2K after | |
| Jun 22, 2026 (view filing) | Jun 18 | 4 days | Leoni MollieChief Medical Officer | SSale | −84.9K | $9.82 | −$834.0K | −31.8%182.3K after | 10b5-1 |
| May 22, 2026 (view filing) | May 21 | 1 day | Powl Brian T.Chief Commercial Officer | SSale | −10.0K | $11.00 | −$110.0K | −5.4%173.6K after | 10b5-1 |
| May 20, 2026 (view filing) | May 19 | 1 day | Ford KathleenChief Operating Officer | SSale | −2.26K | $9.08 | −$20.5K | −1.4%153.6K after | 10b5-1 |
| May 20, 2026 (view filing) | May 19 | 1 day | Powl Brian T.Chief Commercial Officer | SSale | −339 | $9.21 | −$3.12K | −0.2%183.6K after | 10b5-1 |
| May 20, 2026 (view filing) | May 18 | 2 days | Bair Teresa BrophyChief Legal Officer | SSale | −2.26K | $9.38 | −$21.2K | −1.0%226.9K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Kura Oncology, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 10,509,233 | $115.3M | 0.00% | +871,702+9.0% | Added |
| Suvretta Capital Management, LLC | 8,575,422 | $94.1M | 1.98% | 00.0% | Unchanged |
| BVF Inc | 8,445,769 | $92.7M | 2.37% | 00.0% | Unchanged |
| State Street Corp | 5,329,208 | $58.5M | 0.00% | +817,317+18.1% | Added |
| Vanguard Capital Management LLC | 3,916,164 | $43.0M | 0.00% | +130,479+3.4% | Added |
| Armistice Capital, LLC | 3,678,000 | $40.3M | 1.12% | −58,000−1.6% | Reduced |
| AQR Capital Management LLC | 3,126,727 | $34.3M | 0.01% | +1,002,247+47.2% | Added |
| Goldman Sachs Group Inc | 2,265,171 | $24.8M | 0.00% | +831,700+58.0% | Added |
| Geode Capital Management, LLC | 2,229,958 | $24.5M | 0.00% | +195,682+9.6% | Added |
| Alethea Capital Management, LLC | 2,167,938 | $23.8M | 9.85% | +638,569+41.8% | Added |